Top > Search of International Patents > Method for determination of prognosis of prostate cancer, and diagnostic agent for use in the method

Method for determination of prognosis of prostate cancer, and diagnostic agent for use in the method

Foreign code F130007306
File No. 05-44
Posted date Apr 24, 2013
Country United States of America
Application number 22599807
Gazette No. 20090305299
Gazette No. 8080384
Date of filing Mar 30, 2007
Gazette Date Dec 10, 2009
Gazette Date Dec 20, 2011
International application number JP2007057048
International publication number WO2007119606
Date of international filing Mar 30, 2007
Date of international publication Oct 25, 2007
Priority data
  • P2006-104315 (Apr 5, 2006) JP
  • 2007WO-JP57048 (Mar 30, 2007) WO
Title Method for determination of prognosis of prostate cancer, and diagnostic agent for use in the method
Abstract (US8080384)
A method for determining probability that prostate cancer will metastasize, as well as a diagnostic reagent used therefor is disclosed.
It was discovered that the percentage that NF-κB-p65/RelA has the 254th amino acid threonine which is phosphorylated is significantly higher in the prostate cancer cells in the cases where the bone metastasis was observed than in the cases where bone metastasis was not observed.
Thus, the method for determining probability that prostate cancer will metastasize comprises measuring human NF-κB-p65/RelA in which 254th amino acid threonine is phosphorylated, which human NF-κB-p65/RelA is contained in a prostate tissue separated from human.
Scope of claims [claim1]
1. A method for determining probability that a prostate cancer will metastasize, said method comprising measuring human NF-kappa B-p65/RelA in which 254th amino acid threonine is phosphorylated, said human NF-kappa B-p65/RelA being contained in a prostate tissue separated from human, wherein an increase in the levels of human NF-kappa B-p65/RelA in which the 254th amino acid threonine is phosphorylated in a patient compared to the levels of human NF-kappa B-p65/RelA in which the 254th amino acid threonine is phosphorylated in patients not having metastasized prostate cancer indicates an increase in the probability that a prostate cancer will metastasize.
[claim2]
2. The method according to claim 1, carried out by an immunoassay using an antibody or an antigen-binding fragment thereof, said antibody undergoing antigen-antibody reaction with human NF-kappa B-p65/RelA in which 254th amino acid threonine is phosphorylated but not undergoing antigen-antibody reaction with human NF-kappa B-p65/RelA in which 254th amino acid threonine is not phosphorylated.
[claim3]
3. The method according to claim 2, wherein said immunoassay is immunohistochemical staining.
[claim4]
4. The method according to according to any one of claims 1 to 3, wherein the metastasis is bone metastasis.
  • Inventor, and Inventor/Applicant
  • RYO AKIHIDE
  • AOKI ICHIRO
  • SASAKI TAKESHI
  • YOKOHAMA CITY UNIVERSITY
IPC(International Patent Classification)
U.S. Cl./(Sub)
  • G01N033/574C14
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close